EUCTR2009-017858-12-FR进行中（未招募）1 期
A phase 2a proof of concept study comparing three doses of an oral solution of LEO 22811 with a placebo oral solution for the treatment of psoriasis vulgaris
EO Pharma A/S0 个研究点目标入组 64 人开始时间: 2010年3月29日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.1 Signed informed consent has been obtained
- •1.2 Clinical diagnosis of psoriasis vulgaris, for at least 6 months prior to randomisation, and currently covering at least 10% of the body surface area (BSA)
- •1.3 Candidates for systemic anti-psoriatic treatment
- •1.4 Psoriasis Area and Severity Index (PASI) =10
- •1.5 Disease severity of moderate, severe or very severe according to the Investigators’ Global Assessment of disease severity (IGA)
- •1.6 Aged 18 years or above
- •1.7 Any race or ethnicity
- •1.8 Males, surgically sterile females (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or post menopausal females (at least 1 year since last menses)
- •1.9 Attending hospital outpatient clinic or the private practice of a dermatologist.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •2.1 Systemic treatment with biological therapies whether marketed or not with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation:
- •Etanercept – 4 weeks
- •Adalimumab, alefacept, infliximab – 2 months
- •Ustekinumab – 4 months
- •2.2 Systemic treatment with all other therapies (other than biologics) with a possible effect on psoriasis vulgaris (e.g. corticosteroids, retinoids, immunosuppressants, meth-otrexate, cyclosporin or fumaric acid) within 4 weeks prior to randomisation
- •2.3 PUVA therapy within 4 weeks prior to randomisation
- •2.4 UVB therapy within 2 weeks prior to randomisation
- •2.5 Any topical treatment (except for emollients/medicated shampoo) within 2 weeks prior to randomisation
- •2.6 Initiation of, or changes to concomitant medication that could affect psoriasis vulgaris (e.g. beta-blockers, anti-malaria drugs, lithium) 2 weeks prior to randomisation and during the study
- •2.7 Current diagnosis with erythrodermic, exfoliative or pustular psoriasis
- •2.8 Other current skin conditions that may confound the evaluation of psoriasis vulgaris as judged by the Investigator
- •2.9 Generally in good health and does not have any clinically significant cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, haematologic, or gastrointestinal disease, immunologic insufficiency, or other major diseases or current condition which, in the opinion of the Investigator, would put the subject at risk by participating in the study
- •2.10 Current active tuberculosis or latent tuberculosis
- •2.11 Planned exposure to the sun during the study that may affect psoriasis vulgaris
- •2.12 Known malignancy or history of malignancy (other than cervical carcinoma in situ, basal cell or squamous cell carcinoma) within the 5 year period prior to randomisation
- •2.13 Live vaccination within the 4 weeks prior to randomisation
- •2.14 Males who do not agree to use adequate contraception during the study (including follow-up) to ensure their partner does not become pregnant
- •2.15 Known or suspected hypersensitivity to component(s) of investigational products
- •2.16 Current participation in any other interventional clinical trial
- •2.17 Subjects who have received treatment with any non-marketed drug substance (i.e., an agent which has not yet been made available for clinical use following registration) within 4 weeks or 5 half-lives (whichever is longer) prior to randomisation
- •2.18 Previously randomised in this trial
- •2.19 Known or, in the opinion of the Investigator, is unlikely to comply with the Clinical Study Protocol (e.g., alcohol abuse, drug dependency or psychotic state)
研究者
相似试验
尚未招募
不适用
Pilot study for the comparison of three different modalities for the measurement of the range of motion of the shoulder and short term changes of the range of motion of the shoulder after fascia therapyM19.01M19.11M19.21M24.21M24.51M25.61DRKS00022231Klinik für Unfallchirurgie, Universitätsmedizin Greifswald12
已完成
不适用
Pilot study for the comparison of three different modalities for the measurement of the range of motion of the wristRange of motion of the wristDRKS00022220Klinik für Unfallchirurgie, Universitätsmedizin Greifswald13
进行中（未招募）
1 期
This study is being done to test the safety and efficacy of an investigational drug called AZD6738, when taken alone and when taken in combination with another investigational drug called acalabrutinib (also known as ACP-196).EUCTR2016-003737-15-GBAcerta Pharma BV50
进行中（未招募）
1 期
This study is being done to test the safety and efficacy of an investigational drug called AZD6738, when taken alone and when taken in combination with another investigational drug called acalabrutinib (also known as ACP-196).Relapsed or Refractory High-risk Chronic Lymphocytic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10009310Term: CLLSystem Organ Class: 100000004864EUCTR2016-003737-15-PLAcerta Pharma BV50
招募中
1 期
DEUCRALIPichen planusMedDRA version: 20.1Level: PTClassification code: 10030983Term: Oral lichen planus Class: 100000004856MedDRA version: 20.0Level: PTClassification code: 10024429Term: Lichen planus Class: 100000004858CTIS2022-502991-21-00Rheinische Friedrich Wilhelms Universitaet Bonn30